ACER Acer Therapeutics, Inc.

2.950.06 (+2.08%)
IEX real time price: 12:29:27 PM

Quote

Previous Close
$2.89
Day Range
$2.73-$2.98
52 Week Range
$2.88-$34.10
Volume
109,632
Avg Volume
544,149
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$29.76M
Enterprise Value (EV)
-$12.52M
PE Ratio
-
EV/EBITDA
0.58
Price/Sales
-
Price/Book
0.65
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$27.74K
EBITDA
-$21.69M
EPS, ttm
-$2.71
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/12/2019 (25 days)
Debt to Equity
-
Debt
-
Cash
$41.67M
Net Debt
-

Performance

Beta
1.66
200 Day Moving Avg
$20.81
50 Day Moving Avg
$13.66
52 Week Change
-85.38%
YTD Change
-84.45%
1 Month Change
-83.42%
3 Month Change
-85.39%
6 Month Change
-88.44%
1 Year Change
-85.38%
2 Year Change
223.04%
5 Year Change
-83.90%

Share Count

Shares Outstanding
10.1M
Float
-
Restricted Shares
10.1M
Restricted Shares, %
100.00%

Acer Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Christopher Schelling

Website: http://www.acertx.com

Description: Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Newton, MA.

Employees: 23